The United States Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not infringe patents held by Amarin Corporation. The decision on Thursday overturns a lower court ruling and protects the "skinny label" pathway used by generic drugmakers to bypass brand-name patents. This ruling preserves a system that generic firms claim saved payers $2.9 trillion over the last decade by lowering drug costs.
Supreme Court Backs Hikma in Generic Drug Patent Case
The U.S. Supreme Court unanimously overturned a lower court ruling against Hikma Pharmaceuticals, finding its generic version of Vascepa did not infringe on Amarin patents. The decision supports the use of skinny labels to encourage market competition and lower drug prices for American patients.
Xurve View
洞察:
Xurve View











